Friday, 4 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

ECARX (ECX) Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
ECARX (ECX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 8 a.m. ET Call participants Chief Executive Officer — Ziyu Shen Chief Operating Officer — Peter W…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 2025 was a critical inflection point marking the start of ECARX's next phase of sustainable profitable growth

    80% confidence
  • Q1 2026 represents a softer period for automotive consumption following Q4 peak, with seasonal fluctuations typical of the industry

    80% confidence
  • 2025 represents a strategic inflection point in ECARX's evolution, successfully navigating macroeconomic headwinds to deliver second consecutive quarter of positive operating income and EBITDA

    80% confidence
  • Gross margin outlook for 2026 is range of 15-18%

    80% confidence
  • ECARX targets to generate 50% of total revenue from overseas markets by 2030

    80% confidence
  • ECARX expects total revenue for full year 2026 in range of $1.0-1.1 billion, representing 20-30% YoY increase, with commitment to maintain positive operating income throughout 2026

    80% confidence
  • ECARX targets to meaningfully increase share of total revenue from international markets by end of decade

    80% confidence
  • ECARX has broad level of significant opportunities emerging from engagement with European partners, with hope that pipeline will pay well with additional wins that will contribute to revenue in future

    80% confidence
  • ECARX is transforming vehicles into seamlessly integrated information, communication, and transportation devices with vision of becoming a leading AI technology provider in the automotive industry

    80% confidence
  • Overall automotive market in Q1 impacted by policy changes and end user demand shrinking, with some reports showing estimation of 20% decrease or worse in auto wholesale Q1 YoY

    80% confidence
  • Antora platform has obtained key safety and privacy certifications for European market entry

    80% confidence
  • Auto demand has been impacted by weakening of government-supported policies in Q1 2026

    80% confidence
  • ECARX target for 2026 is to continue to generate meaningful annual revenue growth and maintain positive operating income throughout 2026

    80% confidence
  • Partnership with Volkswagen Group continues to progress smoothly with sample development and delivery consistently meeting all targets and exceeding expectations

    80% confidence
  • ECARX is working to obtain relevant regulatory certifications in the US to engage with US automakers

    80% confidence
  • ECARX proudly serves 18 OEMs across 28 brands worldwide

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
ECARX (ECX) Q4 2025 Earnings Call Transcript — Source | Via News | ViaNews EU